벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftazidime pentahydrate 232,8 g - eq. ceftazidime 2000 mg - powder for solution for injection/infusion - 2 g - ceftazidime pentahydrate - ceftazidime

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftazidime pentahydrate 582 mg - eq. ceftazidime 500 mg - powder for solution for injection - 500 mg - ceftazidime pentahydrate - ceftazidime

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 1164.8mg equivalent to 1 g ceftazidime - powder for injection - 1 g - active: ceftazidime pentahydrate 1164.8mg equivalent to 1 g ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 291.2mg equivalent to 250 mg ceftazidime - powder for injection - 250 mg - active: ceftazidime pentahydrate 291.2mg equivalent to 250 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 2329.6mg equivalent to 2 g ceftazidime - powder for injection - 2 g - active: ceftazidime pentahydrate 2329.6mg equivalent to 2 g ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime - powder for injection - 500 mg - active: ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

미국 - 영어 - NLM (National Library of Medicine)

hospira, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 6 g - tazicef (ceftazidime for injection, usp) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: tazicef (ceftazidime for injection, usp) may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. tazicef may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of tazicef (ceftazidime) and other antibacterial drugs,

미국 - 영어 - NLM (National Library of Medicine)

teligent pharma, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 200 mg in 1 ml - fortaz is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: fortaz may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. fortaz may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of fortaz and other antibacterial drugs, fortaz should be used only to treat infections that are proven or strongly suspected

미국 - 영어 - NLM (National Library of Medicine)

hospira, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g - tazicef (ceftazidime for injection, usp) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: tazicef (ceftazidime for injection, usp) may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. tazicef (ceftazidime for injection, usp) may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of tazicef (ceftazidime

이스라엘 - 영어 - Ministry of Health

neopharm (israel) 1996 ltd - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1000 mg/vial - ceftazidime - ceftazidime is indicated for the treatment of the infections listed below in adults and children includingneonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patients on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria (see sections 4.4 and 5.1).ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines regarding the appropriate use of antibacterial agents